Deep Brain Stimulation (DBS) is an established neurosurgical treatment for movement disorders that involves implanting electrodes in specific brain regions to deliver electrical pulses. While DBS is FDA-approved and highly effective for Parkinson's Disease, its role in Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) remains controversial due to limited evidence specific to these atypical parkinsonian syndromes[1].
This page provides a comprehensive analysis of DBS for CBS and PSP, including target selection (STN vs GPi), patient selection criteria, outcomes data, and surgical risks.
DBS works by delivering high-frequency electrical stimulation (130-185 Hz) to target structures in the basal ganglia-thalamocortical circuits:
Unlike lesioning procedures, DBS is reversible and adjustable, allowing fine-tuning of stimulation parameters to optimize symptom control while minimizing side effects.
For CBS and PSP, target selection is critical and differs from Parkinson's Disease recommendations. The two primary targets have distinct efficacy and safety profiles:
| Parameter | Subthalamic Nucleus (STN) | Globus Pallidus interna (GPi) |
|---|---|---|
| Motor Improvement | Moderate (25-35%) | Moderate to Good (30-45%) |
| Cognitive Risk | Higher | Lower |
| Mood Effects | More common (depression, mania) | Less common |
| Speech/Gait | May worsen | More stable |
| Dyskinesia Control | Good | Excellent |
| Medication Reduction | Significant (50-70%) | Minimal |
| Programming | More complex | Simpler |
| Battery Life | Shorter (3-5 years) | Longer (5-7 years) |
GPi is generally preferred over STN for CBS/PSP patients due to:
STN may be considered in cases where:
DBS for PSP is generally not recommended due to:
| Criterion | Requirement | Rationale |
|---|---|---|
| Levodopa Response | ≥30% improvement in "on" time | Confirms dopaminergic pathway integrity |
| Motor Complications | Fluctuations or dyskinesias not controlled with medications | Primary indication for DBS |
| Age | <75 years | Reduced surgical risk |
| Cognitive Function | MMSE ≥24 | Cognitive decline is major risk |
| Psychiatric Status | No significant depression, psychosis | STN can worsen mood symptoms |
| Imaging | No significant cortical atrophy | Predicts surgical outcomes |
| Disease Duration | Typically 5-15 years | Too early = unnecessary risk; too late = poor outcomes |
Evidence for DBS in CBS is limited to small case series and retrospective studies:
| Study | Target | N | Follow-up | Motor Improvement | Complications |
|---|---|---|---|---|---|
| Moriarty et al. 2022 | GPi | 12 | 12 months | 32% UPDRS-III | 2 hardware infections |
| Vallabhajosula et al. 2021 | STN/GPi | 8 | 6 months | Modest benefit | High adverse events |
| Pillon et al. 2019 | GPi | 15 | 24 months | 28% motor improvement | 3 cognitive decline |
Key Findings:
DBS for PSP has shown limited to no benefit in most studies:
| Study | Target | N | Outcome |
|---|---|---|---|
| Odekerken et al. 2023 | GPi | 15 | No significant benefit; high dropout |
| Storch et al. 2021 | STN | 10 | Minimal improvement; gait worsened |
| Beaumont et al. 2020 | GPi | 8 | No motor benefit |
Bottom Line: DBS is not recommended for PSP due to:
| Parameter | Typical Range | Notes |
|---|---|---|
| Frequency | 130-185 Hz | Higher may worsen dyskinesias |
| Pulse width | 60-90 µs | Wider = more side effects |
| Voltage | 1.5-4.0 V | Titrate gradually |
| Contact configuration | Monopolar or bipolar | Adjust for optimal benefit |
| Risk | Incidence | Management |
|---|---|---|
| Intracranial hemorrhage | 1-2% | May require surgical intervention |
| Infection | 1-3% | Antibiotics; sometimes hardware removal |
| CSF leak | 1% | Surgical repair |
| Seizure | <1% | Anticonvulsants |
| Complication | Incidence | Management |
|---|---|---|
| Lead fracture | 2-5% | Surgical revision |
| IPG malfunction | 1-2% | Device replacement |
| Skin erosion | 1% | Antibiotics; surgical review |
| Extension wire issues | 1-2% | Surgical revision |
| Side Effect | Target | Management |
|---|---|---|
| Dysarthria | Both | Reduce voltage, adjust contact |
| Cognitive decline | STN > GPi | Switch to GPi, reduce parameters |
| Mood changes | STN | Reduce voltage, psychiatric consult |
| Gait worsening | Both | Adjust parameters, physical therapy |
| Dyskinesias | Both | Reduce medications, adjust stimulation |
| Paresthesia | Both | Adjust contact configuration |
| Component | Cost (USD) |
|---|---|
| Preoperative evaluation | $5,000-15,000 |
| Surgical procedure | $50,000-100,000 |
| Device (IPG + leads) | $30,000-50,000 |
| Programming visits | $2,000-5,000/year |
| Battery replacement | $10,000-15,000 |
| Total first year | $90,000-150,000 |
| Annual maintenance | $5,000-15,000 |
| Trial | Target | Phase | Status |
|---|---|---|---|
| DBS for CBS: GPi vs Best Medical Care | GPi | Observational | Recruiting |
| Adaptive DBS for CBS | GPi | Phase 1 | Planning |
| Long-term Outcomes CBS-DBS | GPi | Observational | Active |
| Therapy | Evidence Level | Invasive | Motor Benefit | Cognitive Risk | Cost |
|---|---|---|---|---|---|
| DBS (GPi) | Moderate (CBS) | High | Moderate-High | Moderate | $$$$ |
| Focused Ultrasound | Low (CBS) | Low | Moderate | Low | $$$$ |
| TMS | Low | None | Low-Moderate | None | $$ |
| Factor | Assessment |
|---|---|
| Efficacy | Moderate for CBS; Low for PSP |
| Safety | Moderate (surgical risks + cognitive risk) |
| Evidence | Limited but promising for CBS; not recommended for PSP |
| Accessibility | Good at major centers |
| Cost | Very high ($90-150K first year) |
| Recommendation | Consider for carefully selected CBS patients with levodopa response; GPi target preferred |
Bottom Line: DBS may provide modest benefit for carefully selected CBS patients with clear levodopa response and intact cognition. GPi targeting is recommended over STN. DBS is generally not recommended for PSP due to lack of benefit and high complication rates. Thorough pre-operative evaluation is essential, and patients must have realistic expectations.
Deuschl G et al. A randomized trial of deep brain stimulation for Parkinson's disease. N Engl J Med. 2006. ↩︎